|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Medical Neuro-Oncology |
The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030 (M.R.G., J.F.K.); Brain Tumor Center at Duke University, Durham, NC 27710 (H.S.F.); University of California at San Francisco, San Francisco, CA 94143 (M.D.P.); Emory University, Atlanta, GA 30322 (J.J.O.); Children's National Medical Center, The George Washington University, Washington, DC 20010 (G.H.R.); Schering-Plough Research Institute, NJ 07033-1300 (S.L.Z.)
1 Address correspondence and reprint requests to Mark R. Gilbert, Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009.
Abstract
Temozolomide is a novel second-generation oral alkylating agent with demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA). A multicenter phase II trial was conducted to determine the efficacy and safety of temozolomide before radiotherapy in patients with newly diagnosed GBM and AA. Fifty-seven patients (51 adult, 6 pediatric) with newly diagnosed supratentorial GBM or AA were treated with temozolomide (200 mg/m2 per day for 5 consecutive days every 28 days) for a maximum of 4 cycles. All patients were then treated with external beam radiotherapy. Twenty-two patients (39%) achieved objective response, including 6 (11%) with complete response (CR) and 16 (28%) with partial response (PR). Additionally, 18 (32%) patients had stable disease (SD). Of 21 patients (18 adult, 3 pediatric) with AA, 2 (10%) achieved CR, 5 (24%) achieved PR, and 8 (38%) had SD. Among adult patients with AA, the median progression-free and overall survival rates were 7.6 and 23.5 months, respectively. Among 36 patients (33 adult, 3 pediatric) with GBM, 4 (11%) had CR, 11 (31%) had PR, and 10 (28%) had SD. The median progression-free and overall survival rates among adult patients with GBM were 3.9 and 13.2 months, respectively. Temozolomide was safe and well tolerated in adult and pediatric patients. Grades 3 and 4 adverse events were reported in 16 (28%) and 7 (12%) patients, respectively. Temozolomide was safe and effective in treating newly diagnosed GBM and AA before radiotherapy. This pre-irradiation treatment approach appears promising, but will require additional evaluation in comparative studies.
References
Azizi, S.A., and Miyamoto, C. (1998) Principles of treatment of malignant gliomas in adults: An overview. J. Neurovirol. 4,204 -216.[Medline]
Brada, M., Judson, I., Beale, P., Moore, S., Reidenberg, P., Statkevich, P., Dugan, M., Batra, V., and Cutler, D. (1999) Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br. J. Cancer 81,1022 -1030.[CrossRef][Web of Science][Medline]
Burger, P.C., Vogel, F.S., Green, S.B., and Strike, T.A. (1985) Glioblastoma multiforme and anaplastic astrocytoma: Pathologic criteria and prognostic implications. Cancer 56,1106 -1111.[CrossRef][Web of Science][Medline]
Dazzi, C., Cariello, A., Giannini, M., Del Duca, M., Giovanis, P., Fiorentini, G., Leoni, M., Rosti, G., Turci, D., Tienghi, A., Vertogen, B., Zumaglini, F., De Giorgi, U., and Marangolo, M. (2000) A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: A phase II pilot study. Anticancer Res. 20,515 -518.[Web of Science][Medline]
Dhodapkar, M., Rubin, J., Reid, J.M., Burch, P.A., Pitot, H.C., Buckner, J.C., Ames, M.M., and Suman, V.J. (1997) Phase I trial of temozolomide (NSC 362856) in patients with advancedcancer. Clin. Cancer Res. 3,1093 -1100.[Abstract]
Dropcho, E.J., Rosenfeld, S.S., Morawetz, R.B., Vitek, J.,
Brothers, M., Gorum, T., Bell, S., Gillespie, G.Y., Glantz, M., and Mahaley,
M.S., Jr. (1992) Preradiation intracarotid cisplatin treatment of
newly diagnosed anaplastic gliomas. The CNS Cancer Consortium. J.
Clin. Oncol. 10,452
-458.
Duffner, P.K., Horowitz, M.E., Krischer, J.P., Friedman, H.S.,
Burger, P.C., Cohen, M.E., Sanford, R.A., Mulhern, R.K., James, H.E., Freeman,
C.R., Seidel, F.G., and Kun, L.E. (1993) Postoperative
chemotherapy and delayed radiation in children less than three years of age
with malignant brain tumors. N. Engl. J. Med.
328,1725
-1731.
Fine, H.A., Dear, K.B., Loeffler, J.S., Black, P.M., and Canellos, G.P. (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71,2585 -2597.[CrossRef][Web of Science][Medline]
Friedman, H.S., McLendon, R.E., Kerby, T., Dugan, M., Bigner, S.H.,
Henry, A.J., Ashley, D.M., Krischer, J., Lovell, S., Rasheed, K., Marchev, F.,
Seman, A.J., Cokgor, I., Rich, J., Stewart, E., Colvin, O.M., Provenzale,
J.M., Bigner, D.D., Haglund, M.M., Friedman, A.H., and Modrich, P.L.
(1998) DNA mismatch repair and O6-alkylguanine-DNA
alkyltransferase analysis and response to Temodal in newly diagnosed malignant
glioma. J. Clin. Oncol.
16,3851
-3857.
Friedman, H.S., Kerby, T., and Calvert, H. (2000)
Temozolomide and treatment of malignant glioma. Clin. Cancer
Res. 6,2585
-2597.
Gilbert, M., O'Neill, A., Grossman, S., Grunnet, M., Mehta, M., Jubelirer, S., and Hellman, R. (2000) A phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: An Eastern Cooperative Oncology Group study (E2393). J. Neurooncol. 47,145 -152.[CrossRef][Medline]
Greenlee, R.T., Hill-Harmon, M.B., Murray, T., and Thun, M.
(2001) Cancer statistics, 2001. CA. Cancer J.
Clin. 51,15
-36.
Jeremic, B., Shibamoto, Y., Grujicic, D., Milicic, B., Stojanovic, M., Nikolic, N., Dagovic, A., and Aleksandrovic, J. (1999) Pre-irradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high-grade astrocytomas: A phase II study. Radiother. Oncol. 51,27 -33.[CrossRef][Web of Science][Medline]
Kirby, S., Macdonald, D., Fisher, B., Gaspar, L., and Cairncross, G. (1996) Preradiation chemotherapy for malignant glioma in adults. Can. J. Neurol. Sci. 23,123 -127.[Web of Science][Medline]
Lesser, G.J., and Grossman, S.A. (1993) The chemotherapy of adult primary brain tumors. Cancer Treat. Rev. 19,261 -281.[Medline]
Levin, V.A., Silver, P., Hannigan, J., Wara, W.M., Gutin, P.H., Davis, R.L., and Wilson, C.B. (1990) Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys. 18,321 -324.[Web of Science][Medline]
Levin, V.A., Leibel, S.A., and Gutin, P.H. (1997) Neoplasms of the central nervous system. In: DeVita, V.T., Jr., Hellman, S., and Rosenberg, S.A. (Eds.), Cancer: Principles and Practice of Oncology. Fifth edition. Philadelphia: Lippincott-Raven. pp.2022 -2082.
Macdonald, D.R., Cascino, T.L., Schold, S.C., Jr, and Cairncross, J.G. (1990) Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8,1277 -1280.[Abstract]
Marzolini, C., Decosterd, L.A., Shen, F., Gander, M., Leyvraz, S., Bauer, J., Buclin, T., Biollaz, J., and Lejeune, F. (1998) Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: Comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother. Pharmacol. 42,433 -440.[CrossRef][Web of Science][Medline]
Newlands, E.S., Blackledge, G.R., Slack, J.A., Rustin, G.J., Smith, D.B., Stuart, N.S., Quarterman, C.P., Hoffman, R., Stevens, M.F., Brampton, M.H., and Gibson, A.C. (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer 65,287 -291.[Web of Science][Medline]
Newlands, E.S., O'Reilly, S.M., Glaser, M.G., Bower, M., Evans, H., Brock, C., Brampton, M.H., Colquhoun, I., Lewis, P., Rice-Edwards, J.M., Illingworth, R.D., and Richards, P.G. (1996) The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur. J. Cancer 32A,2236 -2241.
O'Reilly, S.M., Newlands, E.S., Glaser, M.G., Brampton, M., Rice-Edwards, J.M., Illingworth, R.D., Richards, P.G., Kennard, C., Colquhoun, I.R., Lewis, P., and Stevens, M.F.G. (1993) Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur. J. Cancer 29A,940 -942.
Patel, M., McCully, C., Godwin, K., and Balis, F. (1995) Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc. Am. Soc. Clin. Oncol. 14, 461. (Abstract)
Recht, L., Fram, R.J., Strauss, G., Fitzgerald, T.J., Liepman, M., Lew, R., Kadish, S., Sherman, D., Wilson, J., Greenberger, J., Egan, P., and Silver, D. (1990) Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum (CDDP) and i.v. BCNU: A phase II trial. Am. J. Clin. Oncol. 13,125 -131.[Web of Science][Medline]
Reid, J.M., Stevens, D.C., Rubin, J., and Ames, M.M.
(1997) Pharmacokinetics of 3–methyl-(triazen-1–yl)
imidazole-4–carboximidefollowing administration of temozolomide to
patients with advanced cancer. Clin. Cancer Res.
3,2393
-2398.
Solero, C.L., Monfardini, S., Brambilla, C., Vaghi, A., Valagussa, P., Morello, G., and Bonadonna, G. (1979) Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin. Trials 2, 43-48.[Medline]
Stupp, R., Dietrich, P.-Y., Ostermann Kraljevic, S., Pica, A.,
Maillard, I., Maeder, P., Meuli, R., Janzer, R., Pizzolato, G., Miralbell, R.,
Porchet, F., Regli, L., de Tribolet, N., Mirimanoff, R.O., and Leyvraz, S.
(2002) Promising survival for patients with newly diagnosed
glioblastoma multiforme treated with concomitant radiation plus temozolomide
followed by adjuvant temozolomide. J. Clin. Oncol.
20,1375
-1382.
Yung, W.K.A., Prados, M.D., Yaya-Tur, R., Rosenfeld, S.S., Brada,
M., Friedman, H.S., Albright, R., Olson, J., Chang, S.M., O'Neill, A.M.,
Friedman, A.H., Bruner, J., Yue, N., Dugan, M., Zaknoen, S., and Levin, V.A.
(1999) Multicenter phase II trial of temozolomide in patients
with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse.
Temodal Brain Tumor Group. J. Clin. Oncol.
17,2762
-2771.
Yung, W.K.A., Albright, R.E., Olson, J., Fredericks, R., Fink, K., Prados, M.D., Brada, M., Spence, A., Hohl, R.J., Shapiro, W., Glantz, M., Greenberg, H., Selker, R.G., Vick, N.A., Rampling, R., Friedman, H., Phillips, P., Bruner, J., Yue, N., Osoba, D., Zaknoen, S., and Levin, V.A. (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83,588 -593.[CrossRef][Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Wick, M. Platten, and M. Weller New (alternative) temozolomide regimens for the treatment of glioma Neuro-oncol, January 1, 2009; 11(1): 69 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Lustig, T. Mikkelsen, G. Lesser, S. Grossman, X. Ye, S. Desideri, J. Fisher, J. Wright, and the New Approaches to Brain Tumor Therapy CNS Cons Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease Neuro-oncol, January 1, 2008; 10(6): 1004 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. L. Chinot, M. Barrie, S. Fuentes, N. Eudes, S. Lancelot, P. Metellus, X. Muracciole, D. Braguer, L. Ouafik, P.-M. Martin, et al. Correlation Between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant Temozolomide J. Clin. Oncol., April 20, 2007; 25(12): 1470 - 1475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Barrie, C. Couprie, H. Dufour, D. Figarella-Branger, X. Muracciole, K. Hoang-Xuan, D. Braguer, P. M. Martin, J. C. Peragut, F. Grisoli, et al. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme Ann. Onc., July 1, 2005; 16(7): 1177 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Brada, S. Ashley, A. Dowe, A. Gonsalves, A. Huchet, G. Pesce, M. Reni, F. Saran, B. Wharram, M. Wilkins, et al. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide Ann. Onc., June 1, 2005; 16(6): 942 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Bobola, J. R. Silber, R. G. Ellenbogen, J. R. Geyer, A. Blank, and R. D. Goff O6-Methylguanine-DNA Methyltransferase, O6-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell Lines Clin. Cancer Res., April 1, 2005; 11(7): 2747 - 2755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Robe, M. Bentires-Alj, M. Bonif, B. Rogister, M. Deprez, H. Haddada, M.-T. N. Khac, O. Jolois, K. Erkmen, M.-P. Merville, et al. In vitro and In vivo Activity of the Nuclear Factor-{kappa}B Inhibitor Sulfasalazine in Human Glioblastomas Clin. Cancer Res., August 15, 2004; 10(16): 5595 - 5603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Raizer, M. G. Malkin, M. Kleber, and L. E. Abrey Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy Neuro-oncol, July 1, 2004; 6(3): 247 - 252. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Broniscer and A. Gajjar Supratentorial High-Grade Astrocytoma and Diffuse Brainstem Glioma: Two Challenges for the Pediatric Oncologist Oncologist, April 1, 2004; 9(2): 197 - 206. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
